ワクチンと免疫療法薬のための新しい戦略としてMHC-Eをターゲットにする
Klaus Früh1, Persephone Borrow2, Geraldine M Gillespie2
1Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA. fruehk@ohsu.edu.
Nature reviews. Immunology
|September 3, 2025
まとめ
メジャー・ヒストコンパティビリティ・コンプレックスE級 (MHC-E) タンパク質は,自然殺人細胞 (NK細胞) やT細胞のような免疫細胞を調節する. MHC-Eの相互作用をターゲットにすることで,新しいがんや感染症の免疫療法やワクチンの可能性が生まれます.
科学分野:
- 免疫学
- 分子生物学
- ワクチン学
背景:
- メジャー・ヒストコンパティビリティ・コンプレックスクラスE (MHC- E) は,自然キラー (NK) とT細胞受容体と相互作用する保存された非ポリモルフなタンパク質です.
- MHC- Eは,慢性ウイルス感染症と癌に対する免疫反応において,抑制性および活性化性受容体の両方を関与させることで役割を果たします.
研究 の 目的:
- 生まれつきの免疫と適応免疫におけるMHC-Eの多面的な役割を検討する.
- 感染症とがんに対するMHC-Eベースの免疫療法とワクチンの可能性を調査する.
主な方法:
- MHC- Eの生物学,NK細胞の相互作用,T細胞の反応,および免疫療法戦略に関する既存の文献のレビュー.
- MHC-Eの抗原提示能力と,MHC-E制限T細胞反応におけるその役割の分析.
主要な成果:
- MHC- EはNK細胞とT細胞の抑制および活性化受容体を誘導し,免疫細胞の活性化に影響を与えます.
- MHC- E 阻害受容体の相互作用をターゲットにすることで,NK 細胞とT 細胞の活性化が強化され,抗腫瘍免疫が改善されます.
- MHC-Eで制限されたCD8+T細胞は,特定の疾患に対して,古典的なMHC分子によって制限された細胞よりも,より広範な有効性を提供することがあります.
結論:
- MHCハプロタイプとは無関係な先天性および適応性免疫を調節するMHC-Eの能力は,普遍的なワクチンおよび免疫療法のための機会を提供します.
- MHC-Eの治療利用は有望ですが,まだ初期段階であり,その生物学に関するさらなる研究が必要であることを強調しています.
関連する概念動画
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Antigens Involved in Adaptive Immunity
667
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
667
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Antigen Processing Pathways
1.3K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...
1.3K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


